Statin Timing Linked to Dementia Risk After Diabetes Diagnosis

Starting statin therapy soon after a diagnosis of type 2 diabetes was associated with a modestly lower long-term risk of dementia in a nationwide Danish registry study.

Researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019 and followed them through 2021. Using a target-trial emulation approach, they compared no statin initiation during the first 5 years after diagnosis with initiation within 1 year or between 1 and 5 years.

During a median follow-up of 7.1 years, 2.7% of participants were diagnosed with dementia. Compared with no statin initiation, initiation within 1 year was associated with a 15% lower relative risk of dementia over 10 years. Initiation between 1 and 5 years was associated with a 10% lower relative risk over 10 years. Findings were similar in women and men.

The results are consistent with the importance of managing low-density lipoprotein cholesterol to reduce cardiovascular risk in people with diabetes. They also suggest that the timing of statin initiation may be relevant when researchers evaluate potential cognitive associations.

Because the study was observational, it cannot establish that statins prevented dementia. Residual bias or unmeasured differences could have influenced the findings despite the analytic design. The results support further research and may inform clinician-patient discussions when statin therapy is otherwise indicated.

Source: European Society of Cardiology. Statins are associated with a lower risk of dementia in patients with type 2 diabetes. News release. Published August 30, 2026. Accessed September 1, 2026.